MedInCell Stock Rises 2.64% Against a Declining CAC 40
The stock of the Montpellier-based biotech company showed a notable increase on Thursday, going against the downward trend of the Paris market. At 22.58 euros during the session, MedInCell has offset some of the decline accumulated in recent weeks, amidst high volatility in European markets.
MedInCell's stock is trading at 22.58 euros this Thursday midday, up by 2.64% compared to the previous day's close. This rebound comes after a challenging week, with the stock having lost nearly 3% over the last seven days and 12% over three months. However, the performance over the past year remains significantly positive, at over 65%.
From a technical standpoint, the price is currently below its 50-day moving average (22.93 euros) and its 200-day moving average (23.57 euros), indicating a still fragile medium-term dynamic. The RSI, at 48, is in a neutral zone, with no overbought or oversold signals. On the Bollinger Bands, the stock is positioned in the upper part of the range (76%), between a lower bound of 19.85 euros and an upper bound of 23.44 euros. A sustained crossing of the resistance identified at 24.94 euros would be a significant bullish signal, while technical support is located at 20.24 euros.
The CAC 40, in contrast, is down 0.81% in the session, at 8196 points. The SBF 120 is down 0.78%. In the healthcare sector, Sanofi is down 0.36% and UCB loses 0.78%, highlighting the uniqueness of MedInCell's movement this Thursday.
Financial Calendar and Market Correlation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The company's financial calendar includes the publication of annual results for the fiscal year 2025-2026 on June 16, followed by the general meeting scheduled for September 10. The results for the first half of the fiscal year 2026-2027 are expected on December 8. These events will be key points of focus to assess the operational and commercial trajectory of the biotech specializing in long-duration injection technologies.
The stock has a beta of -0.10, indicating a very low, or slightly inverse, correlation with market movements. This characteristic is evident in today's session, where MedInCell is moving upwards while the main European indices are in the red. The monthly volatility, measured at 14.58%, reflects significant price swings, typical for a mid-sized company in the biotechnology sector.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
